AOD9604 is a synthetic peptide derived from a specific part of human growth hormone (hGH). It has been studied for its metabolic actions, particularly in relation to fat metabolism. AOD9604 is known for its ability to target areas of the body with high fat levels and assist in weight loss. It mimics the effects of natural growth hormones in regulating fat metabolism. This peptide has shown promise in clinical studies for its potential therapeutic use in obesity treatment.

In addition to its potential metabolic benefits, AOD9604 stands out for its unique ability to avoid triggering an immune system response due to its structural similarity to human growth hormone (HGH). Unlike other peptides, no evidence suggests the body develops antibodies against AOD9604.

Source: PubChem

• Sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe Disulfide bridge Cys7-Cys15
• Molecular Formula: C78H123N23O23S2
• Molecular Weight: 1815.12 g/mol
• PubChem CID: 16131447
• CAS Number: 386264-39-7

1. AOD9604 and Obesity

Studies on genetically obese mice and rats have demonstrated that AOD9604 can directly influence fat metabolism without affecting appetite. In addition, research has shown that AOD9604 can reduce body weight and body fat in obese animals.

Clinical trials are underway to investigate the effects of AOD9604 on human subjects. The results from these trials will provide further insights into the efficacy and safety of this peptide as a potential treatment for obesity.

One study titled “Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans” aimed to examine the safety and tolerability of AOD9604 in human subjects. The study involved the enrollment of 534 participants at 16 Australian hospitals and medical centers. The findings indicated that AOD9604 displayed a very low incidence of adverse events in relation to its intake.

One study, titled “Safety and metabolism of AOD9604, a novel nutraceutical ingredient for improved metabolic health,” investigated the safety and metabolic effects of AOD9604. The research was carried out at Monash University in Clayton, Australia. The study explored the effects of AOD9604 on blood glucose, insulin levels, and lipid metabolism. The results suggested that AOD9604 had positive effects on metabolic health.

Body weight change in obese mice over 14-day treatment period with AOD9604 (squares), HGH (triangles), and placebo (circles).
Source: Oxford Academic

2. Joint Pain and Function

Research implies that AOD9604, when administered through intra-articular injections, may have positive effects on joint pain and function. In a recent study investigating the effects of AOD9604 intra-articular injections, researchers examined the impact of these injections on individuals with collagenase-induced knee osteoarthritis. Scientists notice rapid recovery from lameness in the group that received AOD9604 and HA (hyaluronic acid) injection. This shows that early administration of AOD9604 may provide anti-inflammatory and pain relief benefits.

Additionally, using AOD9604 in combination with other peptides, such as BPC-157, has shown potential for cartilage repair and regenerative properties. This suggests that AOD9604, when paired with specific peptides, may aid in the repair and regeneration of cartilage, further improving joint health.

3. AOD9604 and Heart Disease

Research found that AOD9604 may have potential implications for heart disease and cardiovascular health. Heart disease is a significant health concern associated with morbidity and mortality, particularly in relation to conditions like diabetes and cardiovascular issues. AOD9604, a hexadecapeptide, is being studied as a potential therapy to modify cardiovascular risks.

Obesity, which is often linked to heart disease, is a target of AOD9604’s potential efficacy. Obesity is associated with metabolic and physiological problems such as type 2 diabetes and cardiovascular diseases. By reducing belly fat, suppressing appetite, and aiding weight loss, AOD9604 may indirectly contribute to reducing the risk of heart disease.

While further research is needed to fully understand the effects of AOD9604 on heart disease, evidence suggests that this peptide may have beneficial effects on the heart and cardiovascular health.

How safe is AOD9604?

When it comes to safety, available studies imply that AOD9604 is generally well-tolerated with a low risk of side effects. Research has shown that AOD9604 injections have no known health risks and are considered safe, especially when compared to traditional hormone-based treatments. It has been demonstrated to have a good safety and tolerability profile, comparable to a placebo.

While AOD9604 is generally considered safe, it’s important to note that individual responses can vary. Some potential side effects that have been reported include upset stomach, headaches, and injection site pain. However, these side effects are typically mild and transient.

The above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.

Stier Heike studied biology and holds a PhD in Neurobiology (NMIReutlingen/ University of Hohenheim) and a Master in Bioinformatics (University of Applied Sciences-TFH-Berlin). She worked as a Post-Doc in several national and international Labs in Developmental Neurobiology (NMI-Reutlingen, School of Medicine – University of Utah) and in Bioinformatics (Institute of Bioinformatics – Charité, Berlin).

Dr. Heike pioneered a study on the safety and tolerability of the Hexadecapeptide AOD9604 in Humans. In 2007, she joined A&R where she was responsible for the field of regulatory affairs of herbal medicinal products, with a broad knowledge of the adjacent product categories medical device and supplements. Dr. Heike Stier currently works in the field of regulatory affairs for herbal medicinal products at analyze & realize GmbH.

Stier Heike is being referenced as one of the leading scientists involved in the research and development of AOD9604. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Shop and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. Dr. Heike is listed in [8] under the referenced citations.

1. F. M. Ng, J. Sun, L. Sharma, R. Libinaka, W. J. Jiang, and R. Gianello, “Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone,” Horm. Res., vol. 53, no. 6, pp. 274–278, 2000.
2. H. Stier, E. Vos, and D. Kenley, “Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans,” J. Endocrinol. Metab., vol. 3, no. 1–2, pp. 7-15–15, Apr. 2013. [Journal of Endocrinology & Metabolism]
3. “Obesity drug codenamed AOD9604 highly successful in trials,” News-Medical.net, 16-Dec-2004. [Online]. Available: [Accessed: 24-May-2019].
4. R. Zieba, “[Obesity: a review of currently used antiobesity drugs and new compounds in clinical development],” Postepy Hig. Med. Doswiadczalnej Online, vol. 61, pp. 612–626, Oct. 2007. 
5. M. Heffernan et al., “The Effects of Human GH and Its Lipolytic Fragment (AOD9604) on Lipid Metabolism Following Chronic Treatment in Obese Mice andβ 3-AR Knock-Out Mice,” Endocrinology, vol. 142, no. 12, pp. 5182–5189, Dec. 2001.
6. D. R. Kwon and G. Y. Park, “Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model,” Ann. Clin. Lab. Sci., vol. 45, no. 4, pp. 426–432, Jul. 2015. 
7. M. D. Jensen, “Potential role of new therapies in modifying cardiovascular risk in overweight patients with metabolic risk factors,” Obes. Silver Spring Md, vol. 14 Suppl 3, pp. 143S-149S, Jun. 2006.
8. STIER, H., VOS, E., KENLEY, D.. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. Journal of Endocrinology and Metabolism, North America, 3, apr. 2013.

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATONAL AND EDUCATIONAL PURPOSES ONLY.

The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body.  These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease.  Bodily introduction of any kind into humans or animals is strictly forbidden by law.